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ABSTRACT
Background: To maintain a high standard of patient care, it is essential to
rovide adequate pain management in patients who undergo nasal surgery. Levobupi-
acaine and ropivacaine are relatively new long-acting local anesthetics.
Objective: The aim of this study was to compare the analgesic effect and blood
oss of preincisional levobupivacaine HCl 0.25% and ropivacaine HCl 0.375% in
atients undergoing septorhinoplasty.
Methods: Sixty American Society of Anesthesiologists (ASA) I and II patients
(18–55 years old) who were scheduled for elective open technique septorhinoplasty
under general anesthesia were recruited for this study. The anesthetic technique was
standardized for both groups. Preoperative and postoperative hemoglobin levels were
recorded for all patients. Patients were assigned randomly to 1 of 2 study groups, and
preincisional surgical field infiltration with 5 mL of 0.5% levobupivacaine plus 5 mL
of 0.9% saline (group L; n  30) or 5 mL of 0.75% ropivacaine plus 5 mL of 0.9%
saline (group R; n  30) was performed by the same surgeon. The degree of pain was
measured by visual analogue scale (VAS) for pain and recorded at multiple time
points in all patients after surgery.
Results: The analgesic effect at 2 hours in the postanesthesia care unit (PACU)
nd at 24 hours postoperatively did not differ significantly between the 2 local
nesthetics (P  0.05). Pain scores of patients decreased after the 24 hours in
evobupivacaine group and ropivacaine group when compared with 0-minute VAS
alues, and this was statistically significant (P  0.05). No significant difference was
bserved between groups with respect to the preoperative and postoperative hemo-
lobin (P  0.767 and 0.824, respectively) values.
Conclusions: Local tissue infiltration with 0.25% levobupivacaine or 0.375%
ropivacaine is similarly effective in reducing the postoperative pain associated with
septorhinoplasty. (Curr Ther Res Clin Exp. 2011;72:13-22) © 2011 Elsevier HS Journals,
Inc. All rights reserved.
Accepted for publication February 16, 2011. doi:10.1016/j.curtheres.2011.02.003
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INTRODUCTION
An effective postoperative pain management regimen can prevent pain-related
clinical complications and improve the patient’s quality of life.1–3 Local tissue
infiltration using long-acting anesthetic agents combined with general anesthesia
has improved significantly the management of postoperative pain for patients
undergoing various surgical procedures.4–8 More than half of the nasal surgical
procedures, even under general anesthesia, are performed with the additional use
of local anesthetic medications. When used during general anesthesia, additive
local anesthetics can reduce the need for systemic medication, and intraoperative
bleeding and postoperative pain management can be better controlled.9,10
Levobupivacaine is a member of the amino amide class of local anesthetics and
hemically described as (S)-1-butyl-2-piperidylformo-2, 6-xylidide hydrochlo-
ide.11 In vitro animal studies reported that, injected intravenously, levobupiva-
aine has fewer cardiotoxic effects and fewer toxic effects on the central nervous
ystem (CNS) than both R() bupivacaine and bupivacaine itself.12–14 Studies in
volunteers confirm these results and additionally note minor arrhythmogenic
effects, such as small increases in the PR interval and the corrected QT interval
and less negative inotropic effect than that for rac-bupivacaine as indicated by
changes in stroke index, acceleration index, and ejection fraction.15 The reduced
toxicity of levobupivacaine provides a wider safety margin in the daily clinical
practice both for single shot and for continuous infusion, intraoperatively during
various surgical procedures, and for postoperative pain control.16,17
Ropivacaine is a new amimo amide local anesthetic. It is the monohydrate of
he hydrochloride salt of 1-propyl-2,6-pipecoloxylidide and is prepared as the
ure S-enantiomer. The sensory block provided by ropivacaine is similar to that
roduced by an equivalent dose of bupivacaine in extradural and peripheral nerve
lock.18–20 The lower toxicity on the cardiac system and CNS, when compared
with that of bupivacaine, enables ropivacaine to be used for surgical anesthesia in
concentrations up to 1%.13,14,17,21,22
We hypothesized that postoperative analgesia in septorhinoplasty surgery with
ocal infiltration of levobupivacaine would be more potent than that achieved by
opivacaine with respect to the previous studies that have compared these two
rugs for infiltration anesthesia in various surgical procedures.23,24
The aim of this study was to compare the analgesic effects of preincisional
evobupivacaine HCl 0.25% and ropivacaine HCl 0.375% in patients undergoing
epto-rhinoplasty surgery. Our second goal was to determine whether preinci-
ional injections of levobupivacaine and ropivacaine significantly reduce intraop-
rative blood loss in septorhinoplasty surgery by measuring preoperative and
ostoperative hemoglobin levels.
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C. Bicer et al.METHODS
Study Design
The study was conducted at Erciyes University Medical Faculty Gevher Nesibe
ospital in Kayseri, Turkey, and was approved by the Human Research Ethics
ommittee of Erciyes University. The study was also conducted according to the
elsinki Declaration Guidelines. All patients received a thorough explanation of
he study design and signed an informed consent. All of the drugs used in the
tudy were prepared by the same researcher, who was not involved in the
ntraoperative or postoperative treatment of the patients; the anesthesiologist and
urgeon were blinded to the composition of the solution injected in the surgical
rea. Identical volumes of ropivacaine and levobupivacaine were compared. Med-
cations were similar in appearance with respect to color and viscosity. Also,
yringes themselves were similar in appearance. The blinding process remained
omplete until all data were entered in the trial database and the accuracy of the
ata and the database was confirmed. Afterward, the database was forwarded to
he statistician for analysis.
Patients were hospitalized during the postoperative 24-hour period. Postop-
rative data were collected by the same anesthesiologist, who was blinded to the
ocal anesthetic used.
Sixty American Society of Anesthesiologists (ASA) I and II patients scheduled
or elective open technique septorhinoplasty under general anesthesia, who were
etween 18 and 55 years of age, were recruited for this prospective, randomized,
ouble-blinded study. To be included in the study, consenting patients had to be
n ASA class I or II and needing a septorhinoplasty operation. The exclusion
riteria included a history of significant cardiac, pulmonary, hepatic, or renal
isease; inability to cooperate; chronic drug or alcohol abuse; hypersensitivity to
ny of the drugs used in the study; chronic pain requiring major analgesics; age
18 or 65 years; and weight 45 or 120 kg.
Perioperative conditions were similar in the 2 groups. Subjects did not receive
ny premedication before surgery. During the preoperative visit on the day before
he operation, the patients were introduced to the concept of the visual analogue
cale (VAS), which ranged from 0  no pain to 100  worst pain imaginable.
All patients received infusional therapy consisting of 1000 mL of sterile saline
solution (NaCl 0.9%) throughout the operation. During the operation and 30
minutes postoperatively, standard noninvasive monitoring, including electrocar-
diogram, pulse rate, end-tidal CO2, systolic and diastolic blood pressure mea-
urement, and pulse oximetry, was applied for all the patients. Patient vital signs
ere recorded at before anesthesia induction; after tracheal intubation; at 30, 60,
0, 120, 150, and 180 minutes intraoperatively; and at 10, 20, and 30 minutes
ostoperatively.
For estimating intraoperative blood loss, preoperative and postoperative he-
oglobin levels were recorded for all patients. Postoperative hemoglobin mea-
urements were performed on the evening of the operation.
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Current Therapeutic ResearchIn all 60 patients, anesthesia was induced with fentanyl 3 to 5 g/kg and
ropofol 2 mg/kg, followed by vecuronium 0.1 mg/kg to facilitate tracheal
ntubation. Anesthesia was maintained with sevoflurane 1% to 2% in O2:N2O
1:2). Sufficient muscle relaxation was achieved throughout the operation with
ntermittent doses of vecuronium. Patients were assigned randomly to 1 of 2
tudy groups in a 1:1 ratio, by means of a computer-generated list of random
umbers. The allocation sequence remained concealed for all investigators, pa-
ients, and nursing staff throughout the study period.
Preincisional surgical field infiltration with 5 mL of 0.5% levobupivacaine* plus
mL of 0.9% saline (group L; n  30) or 5 mL of 0.75% ropivacaine† plus 5 mL of
0.9% saline (group R; n  30) was performed by the same surgeon.
At the end of the operation, residual muscle relaxation was reversed with 0.02
mg/kg atropine and 0.04 mg/kg neostigmine. The tracheas of all patients were
extubated in the operating room.
The degree of pain was recorded at PACU (postanesthesia care unit) admission,
as well as after 10 minutes, 20 minutes, 30 minutes, 1 hour, and 2 hours after
surgery. Patients were asked about (or were visually observed for) possible adverse
effects such as postoperative nausea and vomiting, bleeding, dizziness, and allergy
by a clinic nurse who visited each patient at 1-hour intervals during the first 24
hours after surgery. At the same time, the occurrence of untoward events such as
hypotension (decrease in systolic blood pressure from 30% of baseline), hyper-
tension (increase in systolic blood pressure from 30% of baseline), bradycardia
(decrease in heart rate from 20% of baseline), and tachycardia (increase in heart
rate from 20% of baseline) were also recorded. After 2 hours, patients meeting
PACU discharge criteria were transfered to the surgical ward. Pain was evaluated
and recorded by the anesthesiologist at 4, 8, 12, and 24 hours postoperatively. In
the case of inadequate pain relief (VAS was 40), rescue analgesia was given with
2-mg bolus doses of morphine (injected at 20-minute intervals) until adequate
pain relief (VAS was 40) was achieved. The number of morphine injections and
amount of morphine consumption during the first 24 hours after surgery were
recorded. Patients who developed postoperative nausea or vomiting received
intramuscular injections of 10 mg metoclopramide.
Statistical Analysis
According to a previous study of Demiraran et al25 power analysis, 30 patients
er group were enough to detect an average VAS pain score difference of 22 mm
nd standard deviations of 21 and 37 mm in patients’ postoperative 30-minute
ain scores,   0.05 and power  0.8 (MedCalc Software, version 10.1.6,
ariakerke, Belgium).
Statistical analyses were performed using SPSS software version 15.0 (SPSS
nc., Chicago, Illinois) and Sigma Stat 3.5 software (Statcon, Witzenhausen,
*Trademark: Chirocaine® (Abbott, Fornebu, Norway).
†Naropin® 0.75%; 7.5 mg/mL, AstraZeneca AB, Södertälje, Sweden.
16
0d
t
2
t
a
s
h
f
W
G
A
D
C. Bicer et al.Germany). Whether or not the data had normal distribution was assessed using
the Kolmogorov-Smirnov test. Unpaired Student’s t-test was used for a compar-
ison of the parametric data with normal distribution between the groups, and a
repeated measure of analysis of variance was used for serial data and the compar-
ison between pre- and posthemoglobin values within the group. For the evalua-
tion of parametric data without normal distribution, Mann-Whitney U-test was
used; VAS within the group analysis were evaluated by Friedman Test and Dunn’s
test. ASA clasification and gender were evaluated by the 2 test. A P value under
.05 was accepted as statistically significant.
RESULTS
Results of this comparative study refer to a group of 60 patients, aged 18 to 55
years old, who had septorhinoplasty surgery under general anesthesia and prein-
cisional local infiltration analgesia with levobupivacaine and ropivacaine. An
equal volume of local anesthetic solution was infiltrated to the surgical area of
each patient.
No differences in anthropometric parameters (Table I) or in intraoperative and
postoperative hemodynamic variables such as heart rate, end-tidal CO2, systolic and
iastolic arterial blood pressure measurement, and SpO2 were observed between the
wo groups (P  0.05).
Analysis for the VAS pain scores is presented in Table II. The VAS pain scores at
hours in PACU and at 24 hours postoperatively did not differ significantly between
he 2 local anesthetics (P  0.05). The difference between the pain scores at 24 hours
nd 0 minutes in PACU in the levobupivacaine group and the ropivacaine group was
tatistically significant (P  0.05; Table II).
The difference between the postoperative hemoglobin values and the preoperative
emoglobin values in the levobupivacaine and ropivacaine groups was significant (P 0.001
Table I. Anthropometric parameters of the study patients. Data are mean (SD) or number
of patients, as appropriate.
Group L Levobupivacaine
(n  30)
Group R Ropivacaine
(n  30) P
Age (y) 31.2 (9.8) 28 (7.5) 0.160
Height (cm) 170.2 (9.1) 171.6 (8.1) 0.523
eight (kg) 69.8 (15.6) 64.8 (13.2) 0.194
ender (M/F) 15/15 16/14 0.796
SA (I/II) 28/2 28/2 1.000
uration of surgery (min) 149 (34.7) 152 (23.5) 0.690
Values are means (SD) or numbers of patients, as appropriate.
ASA  American Society of Anesthesiologists.or both groups; Table III). No significant difference was observed between groups
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Current Therapeutic Researchwith respect to the preoperative and postoperative hemoglobin values (P 0.767 and
.824, respectively) (Table III).
Five patients (16.6%) in PACU and 3 patients (10%) in the first 24 hours who
eceived levobupivacaine required rescue morphine postoperatively, compared
ith 6 patients (20%) in PACU and 3 patients (10%) in the first 24 hours in the
opivacaine group. No differences were reported between the 2 groups for the
roportion of patients requiring rescue morphine in PACU (P  0.739) and first
24 hours (P  1.000) postoperatively and the total morphine consumption in the first 24
hours (P  0.498).
None of the patients in this study had any of the side effects that have been
reported in the literature to be associated with levobupivacaine and ropivacaine.
Table II. Postoperative pain scores expressed as median (min-max) after levobupivacaine
or ropivacaine local infiltration in septorhinoplasty surgery.
VAS Values
Group L Levobupivacaine
(n  30)
Median (min-max)(mean rank)
Group R Ropivacaine
(n  30)
Median (min-max)(mean rank) P
0 min in PACU 0 (0–60) (5.32) 0 (0–50) (5.75) 0.313
10 min in PACU 5 (0–60) (6.48) 0 (0–50) (5.82) 0.780
20 min in PACU 10 (0–60) (6.57) 0 (0–80) (6.48) 0.729
30 min in PACU 10 (0–60) (6.68) 0 (0–80) (6.32) 0.595
1 h in PACU 10 (0–60) (6.15) 0 (0–60) (6.28) 0.943
2 h in PACU 0 (0–70) (5.58) 0 (0–50) (5.77) 0.852
4 h 0 (0–50) (4.95) 0 (0–50) (5.37) 0.440
8 h 0 (0–50) (4.73) 0 (0–30) (4.73) 0.508
12 h 0 (0–50) (4.48) 0 (0–30) (4.37) 0.553
24 h 0 (0–30) (4.05)* 0 (0–30) (4.12)* 0.530
PACU  postanesthesia care unit; VAS  visual analogue scale.
P  0.05 considered significant.
*P  0.05 decreased when compared to 0 min in PACU VAS values.
Table III. Preoperative and postoperative hemoglobin (g/dL) values.
Group L Levobupivacaine
(n  30)
Group R Ropivacaine
(n  30) P1
Preoperative hemoglobin 14.7 (1.64) 14.8 (1.72) 0.767
Postoperative hemoglobin 13.3 (1.95) 13.2 (1.62) 0.824
P2 0.001 0.001
Data are presented as means (SD).
P  0.05 considered significant.
P1  between groups; P2  within group.
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C. Bicer et al.With regard to systemic effects, no signs of cardiac or CNS toxicity or infection
of the infiltrated areas were observed in any patient. All patients were discharged
uneventfully 24 hours after surgery.
DISCUSSION
This study compared the analgesic effects of local anesthetics levobupivacaine and
ropivacaine for postoperative analgesia after septorhinoplasty surgery. The results of
this prospective, randomized, double-blinded investigation showed that the preinci-
sional infiltration of 10 mL of 0.25% levobupivacaine and 10 mL of 0.375%
ropivacaine have similar effects in managing postoperative pain.
Adequacy of postoperative pain control is one of the most important factors in
determining when a patient can be discharged safely from a surgical facility and has a
major influence on the patient’s ability to resume normal activities of daily living.
Anesthesiologists and surgeons are turning increasingly to nonopioid analgesic techniques
as adjuvants for managing pain during the perioperative period to minimize the adverse
effects of analgesic medications. Pain after nasal and sinus surgery is usually maximal in
the first few postoperative hours.26 During this time, oral opioids are commonly pre-
scribed as analgesics for symptomatic relief, but these drugs are associated frequently with
adverse effects such as sedation, nausea, vomiting, urinary retention, pruritus, and respi-
ratory depression.27 The routine use of peripheral nerve blocks and wound infiltration
with long-acting local anesthetics as an adjuvant to local, regional, and general anesthetic
techniques can improve postoperative pain management after a wide variety of surgical
procedures.28
The vast amount of evidence from in vivo animal studies suggests that the newer
ong-acting local anesthetics have a potentially greater magrin of safety than racemic
upivacaine in the event of an accidental intravascular injection.12 Ohmura et al13
compared the systemic toxicity of bupivacaine, levobupivacaine, and ropivacaine in
anesthetized rats and reported that the systemic toxicity of levobupivacaine is interme-
diate between that of ropivacaine and bupivacaine when administered at the same rate (2
mg/kg/min infusion).
However, a study conducted by Stewart et al,29 which compared the CNS (eg,
dizziness, paresthesia, hypesthesia, ear disorder, headache, dry mouth, tinnitus) and
cardiovascular effects (changes in stroke index, cardiac index, acceleration index, heart rate,
ECG intervals) of levobupivacaine 0.5% and ropivacaine 0.5% when given intravenously
to healthy male volunteers, found that levobupivacaine and ropivacaine produce similar
CNS and cardiovascular effects when infused intravenously at equal concentrations,
milligram doses, and infusion rates. In this study, identical volumes but different
concentrations of ropivacaine and levobupivacaine were compared with regard to their
analgesic effects in a septorhinoplasty model. The maximum doses used were far from the
maximum safe dose for local infiltration in adults. Apparently, this study was designed to
evaluate and compare the potency only and not the safety of the 2 anesthetic agents.
Levobupivacaine has been found to be more potent and longer lasting than ropivacaine for
local infiltration in routine esthetic breast operations such as mastopexy.23
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Current Therapeutic ResearchAlso, Papagiannopoulou et al,24 in a placebo-controlled, randomized, double-
blind study in which they compared the analgesic efficacy of 20 mL ropivacaine
1% and 20 mL levobupivacaine 0.5% for tissue infiltration before trocar place-
ment as a means of improving postoperative pain control after laparoscopic
cholecystectomy, found levobupivacaine more effective than ropivacaine in re-
ducing postoperative pain. In a study comparing the analgesic properties of
locally infiltrated 60 mL of 0.25% levobupivacaine and 50 mL of 0.75% ropi-
vacaine in fleur-de-lys abdominoplasty, it is reported that adequate analgesia is
achieved for at least 4 hours postoperatively by tissue infiltration with either
ropivacaine or levobupivacaine. However, in terms of intensity and duration of
analgesia, levobupivacaine was found to be more effective than ropivacaine in
reducing postoperative pain associated with mini-abdominoplasty.7 Although the
tudies above reported that levobupivacaine has been more effective in reducing
ostoperative pain for tissue infiltration than ropivacaine, the results of the
resent study showed nearly identical VAS scores between the levobupivacaine
nd ropivacaine groups when used for infiltration analgesia in septorhinoplasty
urgery. The proportion of patients requiring rescue morphine and total morphine
onsumption did not differ between the 2 groups.
Demiraran et al25 compared the vasoconstriction and analgesic efficacy of locally
nfiltrated levobupivacaine 0.25% and lidocaine 2% for nasal surgery and reported a
ecrease in VAS scores after 8 hours in the levobupivacaine group and after 24 hours
n the lidocaine group, postoperatively. Similarly, in our study, the decrease in pain
fter 24 hours in both the levobupivacaine and ropivacaine groups may be attributed
o the fact that by interrupting pain cycles early, the patient’s overall pain perception/
nxiety state diminishes, so improved pain control in the first 4 to 6 postoperative
ours has a carryover effect on the ensuing period. This finding is also supported by
he study by Friedman et al26 that compared 100 patients undergoing endscopic sinus
surgery who received either lidocaine (1% or 2%) with epinephrine or bupivacaine
(0.25% or 0.5%) with epinephrine as an anesthetic and for a sphenopalatine block and
reported that pain after nasal and sinus surgery is usually maximal in the first few
postoperative hours.
Using fentanyl during the induction of anesthesia might have been a limitation of this
study, although fentanyl administered during the induction of anesthesia does not affect
postoperative pain, because rhinoplasty requires3 hours. In addition, use of fentanyl during
anesthesia induction also might have been a limitation because of its intraoperative hemody-
namic stabilization effects and its reported ability to reduce intraoperative bleeding in surgical
areas during rhinoplasty. Also, the use of hemoglobin values to evaluate blood loss in patients
who undergo nasal surgery is a limitation, because most patients would not be expected to lose
significant amounts of blood.
The main and secondary outcome measures assessed in the present study were post-
operative pain after septorhinoplasty surgery, additional analgesic drug consumption, and
amount of intraoperative blood loss. In this study, postoperative hemoglobin values of
both groups were decreased when compared with preoperative hemoglobin values, but no
significant difference was observed between the study groups. Although these results
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C. Bicer et al.indirectly suggest that, in these concentrations, levobupivacaine and ropivacaine have
similar vasoconstrictive activities, further studies are needed to evaluate the vasoconstric-
tive activities of both local anesthetics. In the present study, only 16.6% of patients who
received levobupivacaine and 20% of patients who received ropivacain required rescue
morphine in the first postoperative 2 hours. Also, in the 24-hour period 10% of patients
in both treatment groups needed morphine injection. Both levobupivacaine and ropiva-
caine effectively controlled the postoperative pain after septorhinoplasty surgery.
In summary, we conclude that local tissue infiltration with 0.25% levobupivacaine
or 0.375% ropivacaine appears similarly effective in reducing the postoperative pain
associated with septorhinoplasty surgery.
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